Skip to content
Clinical Trials – home
PortugalBack to Portugal

Clinical trials in Montijo

4 clinical trials in Montijo, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

PortugalOur site in PortugalEnsaios-Clinicos.pt(opens in a new tab)
Montijo at a glance
4
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

4 trials in Montijo

Open in trial search

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Zilebesiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Immunisation+3

Not yet recruiting

SARS‑CoV‑2 spike protein vaccine and drug combination study in adults 60 years and older with COVID‑19 and influenza

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED
  • Sponsor:Sanofi Pasteur Inc.

Atrial fibrillation

Not yet recruiting

Prevention of Stroke and Systemic Embolism in Atrial Fibrillation Patients Treated with REGN7508 (cenvacibart) versus Apixaban

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Atrial fibrillation

Not yet recruiting

Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933 in Adults with Atrial Fibrillation Unsuitable for Oral Anticoagulation (Phase 3)

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:REGN7508
  • Sponsor:Regeneron Pharmaceuticals Inc.

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Montijo

What the registry says about research in the country

01 Cardiovascular Diseases

Montijo hosts a focused research effort on cardiovascular diseases, with two active recruiting trials at a single site led by a local investigator.

  • Evaluation of zilebesiran in patients with uncontrolled hypertension and established or high‑risk cardiovascular disease
  • Assessment of the antibody combination REGN7508 and REGN9933 for preventing ischemic stroke and systemic embolism in atrial fibrillation patients
  • Investigation of major bleeding risk associated with the REGN antibody therapy
  • Inclusion of participants with atrial fibrillation, established cardiovascular disease, high cardiovascular risk and hypertension

These studies aim to improve outcomes by testing novel therapies and safety profiles, positioning Montijo as a niche hub for cardiovascular innovation in Portugal.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.